We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Urinary α1 microglobulin level is useful for selecting sodium‐glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes.
- Authors
Koshizaka, Masaya; Ishibashi, Ryoichi; Ishikawa, Ko; Shoji, Mayumi; Ide, Kana; Ide, Shintaro; Kato, Hisaya; Teramoto, Naoya; Terayama, Ryo; Maezawa, Yoshiro; Yokote, Koutaro
- Abstract
Keywords: body composition; clinical trial; metformin; obesity therapy; SGLT2 inhibitor; type 2 diabetes EN body composition clinical trial metformin obesity therapy SGLT2 inhibitor type 2 diabetes 3071 3075 5 09/06/23 20231001 NES 231001 BACKGROUND The Japanese Diabetes Society has released an algorithm for pharmacotherapy for patients with type 2 diabetes (T2D).[1] It recommends metformin and sodium-glucose co-transporter 2 (SGLT2) inhibitors for patients with obesity. Urinary 1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes The results prove that ipragliflozin is effective for reducing VFA in patients with high fasting insulin, low urinary 1MG, or high GPT levels, while metformin is effective for reducing VFA in patients with high HbA1c or urinary 1MG levels. The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
- Subjects
SODIUM-glucose cotransporters; SODIUM-glucose cotransporter 2 inhibitors; TYPE 2 diabetes; METFORMIN; INSULIN sensitivity
- Publication
Diabetes, Obesity & Metabolism, 2023, Vol 25, Issue 10, p3071
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.15188